Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
68Ga-NODAGA-SNA018 PET/CT imaging in breast cancer
ChiCTR2400091303Phase 2Completed
- Sponsor
- Affiliated Huai'an Hospital of Xuzhou Medical University
- Start
- Oct 2024
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of 68Ga-NODAGA-SNA018 in breast cancer, sponsored by Affiliated Huai'an Hospital of Xuzhou Medical University. Primary endpoint: HER2 targeting in breast cancer lesions. Started Oct 2024; status: completed.
02
Drugs
68Ga-NODAGA-SNA018
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2400091303.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400091303.